Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer

Cancer Biology & Therapy
Sundee DeesIsabelle Mercier


Triple-negative breast cancer (TNBC) displays an aggressive clinical course, heightened metastatic potential, and is linked to poor survival rates. Through its lack of expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), this subtype remains unresponsive to traditional targeted therapies. Undesirable and sometimes life-threatening side effects associated with current chemotherapeutic agents warrant the development of more targeted treatment options. Targeting signal transducer and activator of transcription 3 (STAT3), a transcription factor implicated in breast cancer (BCa) progression, has proven to be an efficient approach to halt cancer growth in vitro and in vivo. Currently, there are no FDA-approved STAT3 inhibitors for TNBC. Although pimozide, a FDA-approved antipsychotic drug, has been attributed a role as a STAT3 inhibitor in several cancers, its role on this pathway remains unexplored in TNBC. As a "one size fits all" approach cannot be applied to TNBC therapies due to the heterogeneous nature of this aggressive cancer, we hypothesized that STAT3 could be a novel biomarker of response to guide pimozide therapy. Using human cell lines representative o...Continue Reading


Jul 1, 1986·Journal of Neurology, Neurosurgery, and Psychiatry·L RegeurH Pakkenberg
Jul 14, 2004·Proceedings of the National Academy of Sciences of the United States of America·Tobias N DechowJacqueline F Bromberg
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Jul 29, 2010·Cancer Control : Journal of the Moffitt Cancer Center·Roohi Ismail-Khan, Marilyn M Bui
Nov 12, 2010·The New England Journal of Medicine·William D FoulkesJorge S Reis-Filho
Jun 3, 2011·The Journal of Clinical Investigation·Lauren L C MarottaKornelia Polyak
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Jun 4, 2011·Cellular and Molecular Life Sciences : CMLS·Arun Satelli, Shulin Li
Mar 1, 2012·Drug Discovery Today. Therapeutic Strategies·Tudor I OpreaLarry A Sklar
Sep 18, 2012·Journal of Cancer Science & Therapy·Carlos M Telleria
Mar 28, 2013·Molecular and Cellular Endocrinology·Sarah R WalkerDavid A Frank
Aug 2, 2013·Nature Reviews. Drug Discovery·Gabriella MiklossyJames Turkson
Aug 10, 2013·Trends in Pharmacological Sciences·Subash C GuptaBharat B Aggarwal
Oct 12, 2013·The Journal of Pathology·Brian D Lehmann, Jennifer A Pietenpol
Oct 17, 2013·Molecular Cancer Therapeutics·Helena MistryKalindi Parmar
Nov 8, 2013·BioMed Research International·Mohammad Zahid KamranRajiv P Gude
Dec 7, 2013·Journal of Hematology & Oncology·Muhammad FurqanDelong Liu
Apr 20, 2014·Cancers·Richard L Carpenter, Hui-Wen Lo
May 3, 2014·Arteriosclerosis, Thrombosis, and Vascular Biology·Matteo BecattiClaudia Fiorillo
May 21, 2015·American Society of Clinical Oncology Educational Book·Brian D LehmannAntoinette R Tan
Jul 16, 2015·Expert Review of Proteomics·Sabrina Amar, Gregg B Fields
Jul 16, 2015·Cancer Biology & Medicine·Hanan Ahmed Wahba, Hend Ahmed El-Hadaad
Apr 5, 2016·Breast Cancer : Basic and Clinical Research·Simon B ZeichnerKeerthi Gogineni
Jun 18, 2016·International Journal of Biological Sciences·Valerie FakoXin W Wang
Jul 18, 2017·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Linda SleirePer Øyvind Enger
Feb 7, 2018·Nature Reviews. Clinical Oncology·Daniel E JohnsonJennifer R Grandis
Mar 29, 2018·Cellular & Molecular Biology Letters·Michaela GaloczovaBorivoj Vojtesek
Apr 11, 2018·Therapeutic Advances in Medical Oncology·Ilaria AttiliRafael Rosell
Aug 18, 2018·Drugs in Context·Kelly E McCann, Sara A Hurvitz
Oct 13, 2018·Nature Reviews. Drug Discovery·Sudeep PushpakomMunir Pirmohamed
Dec 7, 2018·F1000Research·Rachel A BattagliaNatasha T Snider
Feb 26, 2019·Oncoscience·Michèle BenieySaima Hassan
May 16, 2019·Journal of Experimental & Clinical Cancer Research : CR·Jiang-Jiang QinWei-Dong Zhang

Related Concepts

Antineoplastic Agents
Biological Markers
Malignant Neoplasm of Breast
Malignant Neoplasms
Neoplasm Metastasis
Epidermal Growth Factor Receptor

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.